Chuangyebang was informed that Zhejiang Maitong Biopharmaceutical Co., Ltd. (hereinafter referred to as “Maitong Bio”) recently announced the completion of the A round of financing. This round of financing was exclusively invested by Chairman Cai Xiang of Longtian Pharmaceutical Group. The funds raised in this round of financing will be used to advance the clinical trials of small molecule inhibitors of the IDH1 pipeline and further accelerate the research and development of the company’s other innovative clinical pipelines.
It is understood that Maitong Bio is an innovative biopharmaceutical company facing the world, focusing on the development of new small molecule targeted anti-tumor drugs by targeting metabolic enzymes related to tumorigenesis. Among them, small molecule inhibitors targeting IDH1 mutations, which are intended to be used for the treatment of gliomas and acute myeloid leukemia, have applied for 3 international (PCT) patents and have been obtained in the United States, Japan, Singapore and China. authorized. Preclinical data show that it has good safety and efficacy in vitro and in vivo in animals. The project is currently in the preparatory stage of IND application, and it is planned to start clinical trials by the end of this year. With the company’s key project IDH1 entering the clinic, Maitong’s development will also enter a new stage. At present, many projects including IDH2 inhibitors and ME3 inhibitors are rapidly advancing. Meanwhile, the pipeline is expected to make a progressive breakthrough this year.
In terms of team, the three scientists and founders of the core team are responsible for the search, demonstration, and drug design and optimization of new drug targets based on their respective research experience in the fields of tumor biology, biochemistry, and medicinal chemistry. Another drug development expert is responsible for the correct control of the standardization and legalization of drug research and development. In addition, the specific research and development work is completed by doctors and masters in biochemistry, medicinal chemistry and pharmacology from domestic and foreign universities.
Cai Xiang, chairman of Longtian Pharmaceutical Group, said that he was very happy to reach a strategic cooperation with Maitong Bio. In the research and development of new targeted anti-tumor drugs, Maitong Bio has always adhered to originality and independent research and development. We fully recognize the staged progress of Maitong Bio. Longtian Pharmaceuticals believes that under the leadership of Academician Zhao Guoping and the concerted efforts of the company’s scientific core team and R&D team, Maitong will surely become a new force in the research and development of new drugs in China. Longtian Pharma actively pays attention to the research and development of new drugs in China, and is willing to carry out multi-dimensional in-depth cooperation with Maitong, promote the construction of an all-round cooperation platform, realize the superposition of advantages and integrated development, and ultimately promote the win-win development of both parties.
Academician Zhao Guoping, founder and chief scientist of Maitong Bio, said that my country’s biopharmaceutical industry started late, and has gone through a difficult journey from imitation to the combination of imitation/introduction. In recent years, the conditions for the development of truly original “first in class” blockbuster drugs with global market competitiveness have gradually matured. Maitong Bio is determined to adhere to the original concept, based on the core patent of small molecule inhibitors targeting the mutation targets of tumor-related metabolic enzymes, and focus on the development direction of innovative anti-tumor small molecule targeted anti-tumor drugs, and gradually form IDH1 inhibitors as the development direction. The research and development focus, the research and development of IDH2 inhibitors and ME3 inhibitors is the follow-up series of project pipelines. Thanks to Longtian Pharmaceuticals’ recognition and support for the company, the company is full of confidence in the follow-up promotion of core products.
Yang Jibin, general manager of Maitong Bio, said that returning to innovation and promoting differentiated innovation oriented by clinical value has become the main theme of the development of my country’s pharmaceutical industry. With the advantages of research and development, genomics and medical big data analysis, small molecule design, etc., and under the guidance of academician Zhao, the founder of science and professors, Maitong has gradually built a comprehensive technical team with a solid professional foundation. With the initial support of local government funds, Maitong completed the experimental data of IDH1 innovative drugs in accordance with the current regulatory requirements for drug application, and expanded the research and development of other drug pipelines at the same time. The investment of Chairman Cai Xiang of Longtian Pharmaceuticals provides another impetus for the further development of Maitong Bio. We expect that innovative drugs targeting IDH1 against glioma and acute myeloid leukemia will enter the clinic smoothly.
media coverage
Entrepreneurial state sprout investment community
Related events
- Financing丨“ Maitong Bio” completed the A round of financing, and Cai Xiang, chairman of Longtian Pharmaceutical Group, made an exclusive investment2022-05-20
- Ruishi Bio completed nearly $100 million in Series A financing2022-05-09
- Yudao Bio announced the completion of $40 million A+ round of financing2022-03-14
- Qinhao Pharma completed hundreds of millions of yuan in Series B financing2022-02-14
- Crystal Egg Bio completed nearly 100 million yuan of Pre-A round of financing2022-01-07
This article is reprinted from: https://readhub.cn/topic/8gaj4qrRznS
This site is for inclusion only, and the copyright belongs to the original author.